← Back to headlines
Zevra Outlines CHMP Reexamination Timing for MIPLYFFA
Zevra Therapeutics has outlined the timing for the CHMP reexamination of MIPLYFFA, with an opinion expected in Q4, and the Orange Book listing for the drug extended to 2041.
6 Aug, 02:32 — 6 Aug, 02:32
Sources
Showing 1 of 1 sources
Related Stories
Climate Catastrophes in Europe Cost Billions, Burdening Citizens
15m ago
Former Google CEO Eric Schmidt Selling Superyacht for €149 Million
16m ago
Berkshire Hathaway's Significant Investment in Alphabet Stock
23m ago
Fabrinet Shares Decline Despite Earnings Beat Due to Margin and Cash Flow Concerns
39m ago